Paola Leonor García

Ms. Paola Leonor García

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PFPedro Félix
Pedro Félix
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
PGPaola Leonor García
Paola Leonor García
PBPablo Zapata Benavides
Pablo Zapata Benavides
CRCristina Padilla Rodríguez-Padilla
Cristina Padilla Rodríguez-Padilla
Immunogenic cell death (ICD) is a type of cell death capable of stimulating immunity against cancer through danger signals that lead to an adaptive immune response. Silver nanoparticles (AgNPs) have been shown to have a cytotoxic effect on cancer cells; however, their mechanism of action is not fully understood. The present study synthesized, characterized, and evaluated the cytotoxic effect of beta-D-glucose-reduced AgNPs (AgNPs-G) against breast cancer (BC) cells in vitro; and assess the immunogenicity of cell death in vitro and in vivo. The results showed that AgNPs-G induce cell death in a dose-dependent manner on BC cell lines. In addition, AgNPs show antiproliferative effects by interfering with the cell cycle. Regarding the detection of damage-associated molecular patterns (DAMPs), it was found that treatment with AgNPs-G induces calreticulin exposure and the release of HSP70, HSP90, HMGB1, and ATP. In vivo, prophylactic vaccination did not prevent tumor establishment; however, tumor weight was significantly lower in AgNPs-G vaccinated mice, while the survival rate increased. In conclusion, we have developed a new method for the synthesis of AgNPs-G, with in vitro antitumor cytotoxic activity on BC cells, accompanied by the release of DAMPs. In vivo, immunization with AgNPs-G failed to induce a complete immune response in mice. Consequently, additional studies are needed to elucidate the mechanism of cell death that leads to the design of strategies and combinations with clinical efficacy.

9 March 2021 in EXCLI Journal
Verified
Journal Article
Open access
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
SSSilvia Santana-Krímskaya
Silvia Santana-Krímskaya
LMLuis Mario Madrigal-De-León
Luis Mario Madrigal-De-León
ECErika Evangelina Coronado-Cerda
Erika Evangelina Coronado-Cerda
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
CRCristina Padilla Rodríguez-Padilla
Cristina Padilla Rodríguez-Padilla
Glioblastoma multiforme is a malignant neoplasm of the brain with poor prognosis. The first-line drug against glioblastoma is the alkylating agent temozolamide (TMZ); unfortunately, treatment resistance and tumor re-incidence are common. In some cases, immunogenic cell death (ICD) inducers can decrease treatment resistance and tumor recurrence by stimulating an antitumor specific immune response. Not all ICD inducers, however, are suitable for glioma patients because of the low permeability of the blood-brain barrier (BBB). Panobinostat (PAN), a histone deacetylase inhibitor and Lophophora williamsii (LW) extract can pass through the BBB and have antitumor properties. The aim of this study is to evaluate the cytotoxic potential of TMZ, PAN and LW extract against the glioma C6 cell line, and its role in the release of damage-associated molecular patterns (DAMPs), which is a hallmark of ICD. Our results indicate that all treatments induce cellular death in a time- and concentration-dependent manner, and that PAN and LW extract induce apoptosis, whereas TMZ induces apoptosis and necrosis. Also, that some of the treatments and their sequential administration induce the release of DAMPs. Furthermore, in a rat glioma model, we observed that all treatments decreased tumor volume, but the in vivo cell death mechanism was not ICD. Our findings indicate that TMZ, PAN, and LW combination have a cytotoxic effect against glioma cells but do not induce ICD.

20 May 2024 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PGPaola Leonor García
Paola Leonor García
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
DTDiana Ginette Zárate Triviño
Diana Ginette Zárate Triviño
SMSara Paola Hernández Martínez
Sara Paola Hernández Martínez
BVBeatriz Elena Castro Valenzuela
Beatriz Elena Castro Valenzuela
CPCristina Rodríguez Padilla
Cristina Rodríguez Padilla
The increasing risk of amputation due to diabetic foot ulcer calls for new therapeutic options; for that, we determined the role of IMMUNEPOTENT CRP (ICRP) and its parts in the wound healing process of superficial wounds in diabetic BALB/c mice. A potency test was performed to confirm the batch of ICRP, and then its parts were separated into pellets, supernatants, and exosomes, and another group of exosomes loaded with insulin was added. Viability and scratch healing were assessed in NIH-3T3, HUVEC, and HACAT cell lines. Diabetes was induced with streptozotocin, and wounds were made by dissecting the back skin. Treatments were topically applied, and closure was monitored; inflammatory cytokines in sera were also evaluated by flow cytometry, and histological analysis was performed by Masson’s staining and immunohistochemistry for p-AKT, p-FOXO, p-P21, and p-TSC2. ICRP pellets and exosomes increased cellular viability, and exosomes and exosome–insulin accelerated scratch healing in vitro. Exosome–insulin releases insulin constantly over time in vitro. In vivo, treatments accelerated wound closure, and better performance was observed in pellet, exosome, and exosome–insulin treatments. Best collagen expression was induced by ICRP. P-AKT and p-FOXO were overexpressed in healing tissues. Inflammatory cytokines were downregulated by all treatments. In conclusion, IMMUNEPOTENT CRP components, especially exosomes, and the process of encapsulation of exosome–insulin accelerate diabetic wound healing and enhance cellular proliferation, collagen production, and inflammation modulation through the phosphorylation of components of the AKT pathway.

Verified
Journal Article
Open access
PDF file
PGPaola Leonor García
Paola Leonor García
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
JAJorge Luis Menchaca Arredondo
Jorge Luis Menchaca Arredondo
PBPablo Zapata Benavides
Pablo Zapata Benavides
CRCristina Padilla Rodríguez-Padilla
Cristina Padilla Rodríguez-Padilla
Chronic wounds in diabetic patients can take months or years to heal, representing a great cost for the healthcare sector and impacts on patients’ lifestyles. Therefore, new effective treatment alternatives are needed to accelerate the healing process. Exosomes are nanovesicles involved in the modulation of signaling pathways that can be produced by any cell and can exert functions similar to the cell of origin. For this reason, IMMUNEPOTENT CRP, which is a bovine spleen leukocyte extract, was analyzed to identify the proteins present and is proposed as a source of exosomes. The exosomes were isolated through ultracentrifugation and shape-size, characterized by atomic force microscopy. The protein content in IMMUNEPOTENT CRP was characterized by EV-trap coupled to liquid chromatography. The in silico analyses for biological pathways, tissue specificity, and transcription factor inducement were performed in GOrilla ontology, Panther ontology, Metascape, and Reactome. It was observed that IMMUNEPOTENT CRP contains diverse peptides. The peptide-containing exosomes had an average size of 60 nm, and exomeres of 30 nm. They had biological activity capable of modulating the wound healing process, through inflammation modulation and the activation of signaling pathways such as PIP3-AKT, as well as other pathways activated by FOXE genes related to specificity in the skin tissue.

Verified
Journal Article
Open access
PDF file
PFPedro Félix
Pedro Félix
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
PGPaola Leonor García
Paola Leonor García
HPHeriberto Prado-Garcia
Heriberto Prado-Garcia
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
CRCristina Padilla Rodríguez-Padilla
Cristina Padilla Rodríguez-Padilla
Breast cancer is the most diagnosed type of cancer worldwide and the second cause of death in women. Triple-negative breast cancer (TNBC) is the most aggressive, and due to the lack of specific targets, it is considered the most challenging subtype to treat and the subtype with the worst prognosis. The present study aims to determine the antitumor effect of beta-D-glucose-reduced silver nanoparticles (AgNPs-G) in a murine model of TNBC, as well as to study its effect on the tumor microenvironment. In an airbag model with 4T1 tumor cell implantation, the administration of AgNPs-G or doxorubicin showed antitumoral activity. Using immunohistochemistry it was demonstrated that treatment with AgNPs-G decreased the expression of PCNA, IDO, and GAL-3 and increased the expression of Caspase-3. In the tumor microenvironment, the treatment increased the percentage of memory T cells and innate effector cells and decreased CD4+ cells and regulatory T cells. There was also an increase in the levels of TNF-α, IFN-γ, and IL-6, while TNF-α was increased in serum. In conclusion, we suggest that AgNPs-G treatment has an antitumor effect that is demonstrated by its ability to remodel the tumor microenvironment in mice with TNBC.

5 March 2025 in REVISTA PENSAMIENTO TRANSFORMACIONAL
Verified
Journal Article
Open access
PDF file
PGPaola Leonor García
Paola Leonor García
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
CRCristina Padilla Rodríguez-Padilla
Cristina Padilla Rodríguez-Padilla
IMMUNEPOTENT-CRP (ICRP) es un extracto dializable de leucocitos bovinos que contiene ácidos nucleicos, exosomas, proteínas y moléculas bioactivas con propiedades antioxidantes, antiinflamatorias, cicatrizantes y antitumorales. Además, modula el estrés oxidativo e inflamación mediante la vía IκB/NF-κB. Materiales y Métodos: Se evaluó de manera sistemática en bases de datos como google scholar, sciencedirect y pubmed la publicaciones relacionadas con los extractos de leucocitos de humano, bovino y porcino. Resultados: El ICRP presenta diversos reportes mostrando eficacia en funciones biológicas como la actividad antimicrobiana con CIM de 0,29 a 0,62 U/mL y citotoxicidad selectiva en líneas leucémicas, preservando las células no cancerosas. Además, de reducir el estrés oxidativo y la inflamación a través de la vía IκB/NF-κB, mostrando más funciones biológicas reportadas que los otros. Discusión: Los resultados destacan el potencial inmunomodulador y antimicrobiano de ICRP, especialmente en oncología e inflamación crónica, gracias a su especificidad terapéutica. Conclusión: El ICRP es un prometedor agente inmunomodulador con aplicaciones potenciales en oncología, enfermedades inflamatorias y regeneración tisular. Se requieren estudios adicionales para confirmar su efectividad clínica.